These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35988070)

  • 1. Glycine transporters in schizophrenia. A new hope or informational noise?
    Zakowicz P; Pawlak J
    Psychiatr Pol; 2022 Apr; 56(2):217-228. PubMed ID: 35988070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate-based therapeutic approaches: inhibitors of glycine transport.
    Lechner SM
    Curr Opin Pharmacol; 2006 Feb; 6(1):75-81. PubMed ID: 16376148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
    Javitt DC
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):468-78. PubMed ID: 19562643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P; Dubroqua S; Yee BK
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
    Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B
    Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).
    Chue P
    Curr Pharm Des; 2013; 19(7):1311-20. PubMed ID: 23194655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.
    Lindsley CW; Wolkenberg SE; Kinney GG
    Curr Top Med Chem; 2006; 6(17):1883-96. PubMed ID: 17017963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycine transport inhibitors in the treatment of schizophrenia.
    Javitt DC
    Handb Exp Pharmacol; 2012; (213):367-99. PubMed ID: 23027421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-cognitive effects of the GlyT1 inhibitor Bitopertin in rodents.
    Deiana S; Hauber W; Munster A; Sommer S; Ferger B; Marti A; Schmid B; Dorner-Ciossek C; Rosenbrock H
    Eur J Pharmacol; 2022 Nov; 935():175306. PubMed ID: 36183855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of striatal dopamine release by glycine transport inhibitors.
    Javitt DC; Hashim A; Sershen H
    Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1).
    Manahan-Vaughan D; Wildförster V; Thomsen C
    Eur J Neurosci; 2008 Oct; 28(7):1342-50. PubMed ID: 18973561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycine transporter type-1 and its inhibitors.
    Harsing LG; Juranyi Z; Gacsalyi I; Tapolcsanyi P; Czompa A; Matyus P
    Curr Med Chem; 2006; 13(9):1017-44. PubMed ID: 16611082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.
    Kinney GG; Sur C; Burno M; Mallorga PJ; Williams JB; Figueroa DJ; Wittmann M; Lemaire W; Conn PJ
    J Neurosci; 2003 Aug; 23(20):7586-91. PubMed ID: 12930797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms.
    Harsing LG; Timar J; Szabo G; Udvari S; Nagy KM; Marko B; Zsilla G; Czompa A; Tapolcsanyi P; Kocsis A; Matyus P
    Curr Pharm Des; 2015; 21(17):2291-303. PubMed ID: 25578890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
    Pei JC; Hung WL; Lin BX; Shih MH; Lu LY; Luo DZ; Tai HC; Studer V; Min MY; Lai WS
    J Psychopharmacol; 2019 Oct; 33(10):1288-1302. PubMed ID: 31294644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.